MultiValent Biotherapies, Inc., 2026-03-02
An SEC Form D private-offering notice from Los Altos, CA, an undisclosed offering target in Biotech. Filed 2026-03-02. The source filing is one click away. For companies that filed this week, open the live feed.
What this filing says
A biotechnology company developing targeted peptide drug conjugate therapies for cancer, including a prostate cancer treatment licensed from Coherent Biopharma.
This is a public SEC Form D private-offering notice, the filer's own statement to the SEC. Amounts are offering targets, not confirmed closes. Takeoff Radar pulls Form D nightly from EDGAR and links every filing to its source.
Other Form D filings from the same week
each with its own page and its own EDGAR source- Ember LifeSciences, Inc., 2026-03-03, $50M, Westlake Village, CA
- HUME SUPERNATURAL, INC., 2026-03-03, $5M, San Diego, CA
- Aegle Therapeutics Corp, 2026-03-03, $700K, Woburn, MA
- Newwork Software Inc., 2026-03-02, $1.2M, Palo Alto, CA
- Haku Bio, Inc., 2026-03-02, Arlington, MA
- Ventaris Surgical, Inc., 2026-03-02, $30.7M, San Carlos, CA
The Monday digest, free
A summary of who raised money last week: the ones worth a call first, then every company that filed, by state and sector. One email, Monday mornings. No spam, unsubscribe anytime.
By subscribing you agree to our Terms and Privacy Policy.